Fintech PR
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
FN Media Group Presents USA News Group News Commentary
VANCOUVER, BC, March 14, 2024 /PRNewswire/ — USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Recently, in late 2023, researchers at the Mayo Clinic made a discovery that advances knowledge of how pancreatic cancer spreads and identified a new potential therapeutic target along the way. With the American Cancer Society projecting a record year for new cancer cases in 2024, and Europe facing a pancreatic cancer emergency, it’s important to focus on the advances being made in the biotech sector that are giving hope to patients and their families. Among the developers making gains include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), ImmunityBio, Inc. (NASDAQ: IBRX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Nuvation Bio Inc. (NYSE: NUVB).
There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13%. Among the therapy developers that have garnered accolades and support from PanCAN is Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), which late last year took home a US$5 million Therapeutic Accelerator Award based on the promising results being delivered by its flagship asset, pelareorep.
Since winning the award, Oncolytics has moved to make an amendment to its ongoing GOBLET gastrointestinal cancer study to include a new (fifth) cohort. This new cohort will evaluate the immunotherapy asset pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) both with and without atezolizumab (Tecentriq®) in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC).
“We are enthusiastic to have the support of PanCAN to expand the evaluation of pelareorep in pancreatic cancer and explore mFOLFIRINOX as another combination that could improve outcomes for patients,” said Dr. Matt Coffey, President and CEO of Oncolytics. “Evaluating pelareorep in combination with these widely used regimens is an important step in our broad clinical development program. Last fall, we reported a 62% objective response rate for the GOBLET PDAC cohort studying pelareorep in combination with the checkpoint inhibitor atezolizumab in addition to gemcitabine and nab-paclitaxel. This response is about three times that of historical controls and forms the basis of the registrational program, expected to begin this year.”
Oncolytics is conducting the GOBLET trial to investigate the effectiveness of pelareorep in enhancing the treatment of pancreatic cancer, a disease known for its poor 5-year survival rate. This is largely due to the cancer’s ability to hide from the immune system and create an environment that suppresses immune response. In late 2022, the FDA granted pelareorep a fast track designation, acknowledging its potential to stimulate both the innate and adaptive immune systems and alter the tumor microenvironment. This makes pelareorep a promising candidate for combination therapy.
“This study is designed to evaluate whether pelareorep can enhance outcomes in patients receiving mFOLFIRINOX, one of the most commonly used metastatic pancreatic cancer treatments,” said Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics. “Combining pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic cancer program and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients.”
After discontinuing development of its monoclonal antibody NIS793 for the treatment of patients with pancreatic cancer, Novartis AG (NYSE: NVS) has opened 2024 with positive data from its Lutathera asset. In a mid-January release, Novartis announced that Lutathera significantly reduced the risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors.
“These positive results for Lutathera are practice-changing and offer new first-line treatment data for patients who have a significant unmet need,” said Dr. Simron Singh, Associate Professor of Medicine at the University of Toronto and co-founder of the Susan Leslie Clinic for Neuroendocrine Tumours at the Odette Cancer Centre, Sunnybrook Health Sciences Centre, Ontario, Canada. “This study confirms the clinical benefit of first-line radioligand therapy for newly diagnosed patients living with these types of advanced GEP-NETs. These findings should instill confidence among physicians in using Lutathera as a first-line treatment for patients with this life-threatening type of cancer.”
Back in early 2022, ImmunityBio, Inc. (NASDAQ: IBRX) showed promising results for its Nant Pancreatic Cancer Vaccine. Now, in February 2024, ImmunityBio has announced full accrual of its first two phases of a cancer vaccine trial in participants with Lynch Syndrome and the initiation of a randomized control phase of the trial. Lynch Syndrome is one of the most common hereditary cancer syndromes, occurring in 1 in every 300 Americans. People with Lynch Syndrome can not only develop colorectal cancer 20 years prior to the average age of diagnosis for that form of cancer but are also at an increased risk of developing many other types of cancers, including pancreatic.
“We are encouraged by how rapidly this study has been able to enroll participants,” said Asad Umar, D.V.M., Ph.D., a senior advisor to the Director for Translational Research in NCI’s Division of Cancer Prevention (DCP) and a scientific lead for the trial. “It is a strong indication of an unmet need and of the willingness of participants to help science make new discoveries in the area of cancer prevention.”
Moving on from a disastrous year in 2023, Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is resurrecting its asset zunsemetinib as a potential cancer treatment. As per the company’s last corporate update of 2023, Aclaris now plans to explore zunsemetinib as a potential treatment for pancreatic cancer and metastatic breast cancer.
“Throughout our history, Aclaris has remained focused on developing novel drugs where there is a lack of satisfactory treatment options,” said Dr. Neal Walker, Co-Founder, Chairman, and Interim CEO of Aclaris in a January 2024 strategic business review. “We are well capitalized and we have recently taken the hard but necessary steps to streamline our operations to reduce costs and preserve capital in order to put Aclaris in an optimal position for the future.”
In early January 2024, the FDA cleared the investigational new drug (IND) application of Nuvation Bio Inc. (NYSE: NUVB) to evaluate its first clinical candidate from its novel drug-drug conjugate (DDC) platform, NUV-1511.
“This IND clearance expands our clinical pipeline and validates the approach of our proprietary DDC platform to design potent oncology-focused chimeric small molecules which combine tumor-targeting specificity with the anti-cancer activity of known oncology agents,” said David Hung, M.D., Founder, President, and CEO of Nuvation Bio. “We believe NUV-1511 has the potential to provide favorable clinical benefit for patients with various solid tumors and we look forward to initiating the Phase 1/2 study.”
The initial part of the Phase 1/2 study will assess safety and tolerability and investigate the potential effectiveness in patients with advanced solid tumors. It will focus on patients with pancreatic cancer, HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and platinum-resistant ovarian cancer (PROC).
Nuvation is already undergoing dosing in the Phase 1 monotherapy study of NUV-868 in solid tumors in patients with pancreatic cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer and other solid tumors.
“We remain focused on strong clinical execution of our NUV-868 program for advanced solid tumors,” said Hung in his company’s Q3 2023 business update.
Article Source: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/
Article Source:
USA News Group
http://USAnewsgroup.com [email protected]
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact Information:
FN Media Group, LLC
Media Contact e-mail:
[email protected]
U.S. Phone: +1(954)345-0611
View original content:https://www.prnewswire.co.uk/news-releases/biotechs-role-in-addressing-the-pancreatic-cancer-emergency-302089066.html
Fintech PR
IBN Technologies LLC Steps in to Support Clients After Bench Accounting’s Unexpected Closure
MIAMI, Dec. 30, 2024 /PRNewswire/ — Businesses and industries are currently facing the challenge of finding a reliable partner to manage their financial needs due to recent developments. It is crucial for them to search for trustworthy solutions that can ensure financial stability during this uncertain time. Exploring reviews and seeking bench accounting alternative accounting services have become priorities for businesses aiming to maintain uninterrupted financial operations. Partnering with a dependable and efficient service provider is essential for sustained success.
IBN Technologies LLC emerges as a trusted solution, offering comprehensive and customized financial support to businesses across industries. Specializing in outsourced bookkeeping and accounting services, IBN ensures a seamless transition for those affected by recent changes. With decades of experience, the company delivers precision, reliability, and tailored financial strategies to meet the unique needs of each client.
Searching for Bench Accounting alternatives?
IBN Technologies LLC offers seamless outsourcing bookkeeping services to keep your business running smoothly.
Get 30-Minute Free Consultation: https://www.ibntech.com/free-consultation/?pr=prnewswire
A Wide Range of Financial Services Designed for Success
IBN Technologies provides a full spectrum of services to meet the diverse needs of today’s businesses, such as:
- Accurate Bookkeeping: Delivering dependable financial management tailored to meet the dynamic needs of businesses, ensuring precision and timely execution.
- Expert Tax Preparation: Providing compliance-driven, strategic tax solutions designed to maximize deductions and unlock greater savings.
- Effortless Payroll Solutions: Offering streamlined and hassle-free payroll services to ensure seamless employee compensation and operational efficiency.
- Strategic Financial Consulting: Empowering businesses with actionable insights and tax strategies to drive smarter decisions and sustainable growth.
The Impact on the Growth Market
At IBN Technologies, we understand the crucial role that bookkeeping accounting services play in helping businesses make informed decisions, plan for the future, and achieve sustained growth. We recognize the challenges that arise when a trusted provider like Bench Accounting suddenly ceases its operations, leaving businesses in a state of uncertainty.
We are here to ensuring that your reporting deadlines are met, tax compliance is maintained, and operational bottlenecks are minimized.
With our comprehensive range of bookkeeping accounting services, we provide the expertise and guidance necessary to navigate through these disruptions. Our dedicated professionals will work closely with you to understand your unique requirements and tailor our solutions accordingly.
IBN Technologies LLC: A Trusted Partner for the Growth Market
IBN Technologies LLC is committed to helping businesses navigate these turbulent times with tailored financial services. With expertise in outsourced bookkeeping and accounting services, IBN provides scalable solutions designed to meet the dynamic needs of growing companies.
“We understand how vital accurate and timely financial management is for businesses in the growth market,” says Ajay Mehta, CEO of IBN Technologies LLC. He believes that “IBN Technologies team is here to ensure that companies not only recover from this disruption but also emerge stronger, with systems and processes that are built for resilience and success.”
Read or E-book:
Catch-Up Bookkeeping: A Step-by-Step Guide to Financial Clarity & Tax Success
Why Choose IBN Technologies LLC?
- Seamless Onboarding: IBN ensures a smooth transition, minimizing downtime and ensuring uninterrupted financial operations.
- Customized Solutions: From startups to medium-sized businesses, IBN customizes its bookkeeping and accounting services to align with each client’s unique needs.
- Growth-Focused Support: IBN helps businesses scale with confidence by providing insights and strategic advisory services that drive financial clarity.
As businesses in the growth market face this period of change, IBN Technologies LLC offers the stability and expertise needed to turn challenges into opportunities. With IBN as a trusted partner, businesses can focus on what matters most achieving their growth ambitions.
Why Choose IBN Technologies LLC?
IBN Technologies LLC combines advanced technology with a client-first approach to deliver reliable, tailored financial solutions. With a skilled team and a commitment to excellence, businesses can trust IBN to provide the stability and support needed to navigate challenges and thrive.
Our expertise allows us to deliver innovative, customized solutions that align with each client’s goals. “We ensure our clients’ operations run smoothly, no matter the obstacles,” said Ajay Mehta, CEO of IBN Technologies LLC.
About IBN Technologies
IBN Technologies LLC, an outsourcing specialist with 25 years of experience, serves clients across the United States, United Kingdom, Middle East, and India. Renowned for its expertise in RPA, Intelligent process automation includes AP Automation services like P2P, Q2C, and Record-to-Report. IBN Technologies provides solutions compliant with ISO 9001:2015, 27001:2022, CMMI-5, and GDPR standards. The company has established itself as a leading provider of IT, KPO, and BPO outsourcing services in outsource bookkeeping services, including CPAs, hedge funds, alternative investments, banking, travel, human resources, and retail industries. It offers customized solutions that drive efficiency and growth.
Contact Details:
Pradip
[email protected]
+1 – 844 – 644 – 8440
USA:
IBN Technologies LLC
66 West Flagler Street Suite 900 Miami, FL 33130
India: Global Delivery Centre
IBN Technologies Limited
Kohinoor House, 2nd floor,
691/A/1B, Plot no. 7,
Bibwewadi Road, Pune-411037
Logo – https://mma.prnewswire.com/media/2581946/5094519/IBN_Technologies_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ibn-technologies-llc-steps-in-to-support-clients-after-bench-accountings-unexpected-closure-302340295.html
Fintech PR
IBN Technologies Steps Up to Support Small Businesses Following Bench Accounting’s Sudden Shutdown
MIAMI, Dec. 30, 2024 /PRNewswire/ — The unexpected closure of Bench Accounting has left thousands of small businesses scrambling to find reliable financial and accounting outsourcing services. This sudden disruption has created a significant gap, leaving many businesses without the external support they once relied on. Announced under the leadership of Bench’s CEO, the closure has forced countless organizations to seek dependable alternatives to manage their financial operations effectively.
In response to this void, IBN Technologies LLC, a global leader in finance and accounting outsourcing, is stepping up to provide tools, expertise, and support small businesses need. With their proven track record and tailored solutions, IBN Technologies ensures that businesses can maintain financial stability and focus on growth during this challenging time.
IBN technologies are a Bench Accounting Alternative
With over 25 years of experience delivering cutting-edge finance and accounting solutions, IBN Technologies is uniquely positioned to provide comprehensive support for businesses impacted by this industry disruption. The company’s scalable and technology-driven services are designed to empower small businesses, enabling them to overcome challenges and achieve long-term stability.
“At IBN Technologies, we empathize with the concerns of small businesses following the recent closure of Bench Accounting,” stated Ajay Mehta, CEO of IBN Technologies. “Our utmost priority is to stand beside these businesses as a reliable partner, offering them the necessary financial expertise to overcome their challenges and forge ahead with confidence.”
Take control of your finances today! Book a free 30-minute consultation with our experts – https://www.ibntech.com/free-consultation/ ?pr=prnewswire
Comprehensive Solutions Customized to Small Businesses
IBN Technologies offers a comprehensive suite of finance and accounting services customized to meet the unique needs of small businesses, including:
- Bookkeeping and Accounting: Seamless bookkeeping services to maintain accurate, compliant financial records effortlessly.
- Payroll Management: Precision payroll processing customized to the specific needs of your workforce.
- Tax Preparation and Filing: Expert assistance to ensure tax compliance while maximizing savings.
- Virtual CFO Services: Strategic financial planning and insights without the cost of a full-time CFO.
- Financial Reporting and Analysis: Real-time insights into financial performance to support smarter, informed decisions.
Rebuilding Confidence in Financial Management
Rebuilding confidence in financial management begins with IBN Technologies. They provide expertise and tools that are needed to streamline business processes, ensure accuracy, and take full control of your finances. Trust IBN Technologies customized solutions to bring stability and drive growth for your business.
“Our mission is to simplify financial management for small businesses while delivering unmatched value,” added by Ajay Mehta. “During this challenging time of Bench Accounting crunch base, we want to extend our unwavering support to all affected businesses. At IBN Technologies, we are committed to being your guiding light throughout this journey, providing the assistance you need at every step.”
About IBN Technologies
With 25 years of industry experience, IBN Technologies has established itself as an outsourcing specialist serving clients across the United States, United Kingdom, Middle East, and India. The company’s solutions adhere to rigorous international standards, including AP Automation services like P2P, Q2C, and Record-to-Report. IBN Technologies provides solutions compliant with ISO 9001:2015, 27001:2022, CMMI-5, and GDPR standard. Their comprehensive service portfolio encompasses IT, KPO, and BPO outsourcing services, specializing in finance and accounting solutions for CPAs, hedge funds, alternative investments, banking, travel, human resources, and retail industries.
For businesses seeking to optimize their financial operations through AP automation, IBN Technologies provides expert guidance and support throughout the digital transformation journey, ensuring seamless integration and maximum operational efficiency.
Contact Details:
Pradip
[email protected]
+1 – 844 – 644 – 8440
USA: IBN Technologies LLC
66 West Flagler Street Suite 900 Miami, FL 33130
India: Global Delivery Centre
IBN Technologies Limited
Kohinoor House, 2nd floor,
691/A/1B, Plot no. 7,
Bibwewadi Road, Pune-411037
Logo: https://mma.prnewswire.com/media/2581946/IBN_Technologies_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ibn-technologies-steps-up-to-support-small-businesses-following-bench-accountings-sudden-shutdown-302340287.html
SINGAPORE, Dec. 30, 2024 /PRNewswire/ — Matrixdock, Asia’s real-world asset (RWA) tokenization leader, announces the integration of its flagship gold token, XAUm, with Binance Wallet, one of the world’s leading digital asset wallets. This development builds on previous integrations with centralized exchange Web3 wallets like OKX and crypto wallets like MetaMask, reinforcing Matrixdock’s commitment to making gold investments more secure, efficient, and accessible for hundreds of millions of global users.
At the core of this integration is XAUm, a token fully backed by London Bullion Market Association (LBMA)- accredited gold bars with a minimum fineness of 99.99%. Each XAUm token represents one troy ounce of gold. These gold reserves are securely stored in Brink’s vaults in Hong Kong and Singapore, offering token holders the option to redeem XAUm for physical gold.
Purpose-built for Web3 compatibility and the multi-chain ecosystem, XAUm seamlessly blends blockchain innovation with user-centric design. Its robust proof-of-reserve transparency, efficient multi-chain reserve management, and enhanced interoperability inspire trust and elevate gold from a static asset to a dynamic, multifunctional financial instrument in the digital economy.
This integration with Binance Wallet builds on previous developments within Binance’s ecosystem, including decentralized exchanges and lending platforms. The goal is to make XAUm a benchmark for modern gold investments, providing an efficient and trusted solution that redefines asset efficiency and financial equality.
Binance Wallet enhances this vision by offering a secure and intuitive entry point to Web3. Users can manage digital assets, perform cross-chain token swaps, and earn yields effortlessly. With a simple setup process via the Binance app, the wallet eliminates the need for seed phrases or private keys, furthermore, it utilizes Multi-Party Computation (MPC) technology to enhance secure transactions.
Through this integration, individuals worldwide are able to buy, own, and trade gold conveniently with a mobile device. By leveraging Web3 technology and the multi-chain ecosystem, Matrixdock and Binance Wallet set a new standard for modern gold investments, driving financial equality and innovation.
About Matrixdock
Founded in February 2023 by Matrixport, Matrixdock is Asia’s RWA leader that modernizes financial instruments through advanced tokenization technology. As the first in Asia to introduce a tokenized short-term treasury bill product, STBT, earned the Ecosystem Excellence TADS Award in 2023 for Trading & Liquidity Solutions. In 2024, it launched a one-of-a-kind Tokenized Gold token, XAUm, modernizing traditional gold investment into a dynamic, multifunctional digital asset.
Photo – https://mma.prnewswire.com/media/2587828/XAUm_Gold_token_matrixdock_binance_wallet.jpg
View original content:https://www.prnewswire.co.uk/news-releases/matrixdock-integrates-xaum-gold-token-with-binance-wallet-to-advance-financial-equality-302340189.html
-
Fintech PR7 days agoBybit Champions Web3 Innovation and Strengthens Ties with Asia’s Crypto Community at Taipei Blockchain Week
-
Fintech PR7 days ago2025 Will See Increased QR Code Payments but Payment Card IC ASPs Will Not Return to Pre-Covid Levels
-
Fintech PR5 days agoMarkets Show Resilience Ahead of End-of-Year Options Expirations: Bybit x Block Scholes Crypto Derivatives Report
-
Fintech PR5 days ago2024 Global Youth Design Contest on Chinese Characters Themed “Guiyang in Characters” Successfully Concluded
-
Fintech PR5 days agoSinopec Completes Construction of China’s Largest Petrochemical Industrial Base
-
Fintech PR4 days agoXinhua Silk Road: Conference on deepening financial openness and co-op in Northeast Asia held in NE. China’s Shenyang
-
Fintech PR4 days agoBybit Web3 Wallet Integrates Tonstakers: The First of Its TON Staking Offerings to Expand DeFi Opportunities
-
Fintech PR5 days agoWSPN Appoints Former EY Global Chief Innovation Officer Jeff Wong as Independent Director